Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009379 | 1.00 | GPR139 (0.52) | GPR139FOLH1SLC6A5SLC6A9ROCK2 | |
| SCHEMBL6277441 | 1.00 | GPR139 (0.52) | GPR139FOLH1SLC6A5SLC6A9ROCK2 | |
| SCHEMBL29639754 | 0.90 | LNPEP (0.52) | FOLH1SLC6A5ERAP2LNPEPERAP1 | |
| SCHEMBL10518047 | 0.87 | ROCK2 (0.56) | FOLH1ROCK2GRIN1GRIN2A | |
| SCHEMBL10518055 | 0.87 | ROCK2 (0.56) | FOLH1ROCK2GRIN1GRIN2A | |
| SCHEMBL607886 | 0.86 | ITGB3 (0.60) | FOLH1ERAP2LNPEPGRIN1GRIN2A | |
| SCHEMBL607885 | 0.86 | ITGB3 (0.60) | FOLH1ERAP2LNPEPGRIN1GRIN2A | |
| SCHEMBL23113773 | 0.84 | GPR139 (0.47) | GPR139FOLH1ITGB3ITGA2BCTSB | |
| SCHEMBL23113771 | 0.84 | GPR139 (0.47) | GPR139FOLH1ITGB3ITGA2BCTSB | |
| SCHEMBL4601261 | 0.83 | F2 (0.55) | SLC6A9ERAP2LNPEPGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383885-A4 | METHOD OF PREPARATION OF STABILIZED THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) AND METHODS OF USE THEREOF | AMERICAN DIAGNOSTICA INC (US) | 2005-11-30 | — | — | EP | claimed |
| US-20050260219-A1 | Carboxypeptidases B from anopheles gambiae. compositions comprising them, vaccine applications and use as therapeutical targets | INSTITUT PASTEUR (FR) | 2005-11-24 | — | — | US | claimed |
| WO-2005103243-A2 | CARBOXYPEPTIDASES B FROM ANOPHELES GAMBIAE. COMPOSITIONS COMPRISING THEM, VACCINE APPLICATIONS AND USE AS THERAPEUTICAL TARGETS | INSTITUT PASTEUR (FR) | 2005-11-03 | — | — | WO | claimed |
| US-6808927-B2 | Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof | AMERICAN DIAGNOSTICA, INC. | 2004-10-26 | — | — | US | claimed |
| EP-1383885-A1 | METHOD OF PREPARATION OF STABILIZED THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) AND METHODS OF USE THEREOF | AMERICAN DIAGNOSTICA, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002099098-A1 | METHOD OF PREPARATION OF STABILIZED THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) AND METHODS OF USE THEREOF | AMERICAN DIAGNOSTICA, INC (US) | 2002-12-12 | — | — | WO | claimed |
| US-20020177560-A1 | Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof | BIOMEDICA DIAGNOSTICS INC. (CA) | 2002-11-28 | — | — | US | claimed |
| JP-62215599-A | — | — | None | — | — | JP | disclosed |
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | Technische Universität München (DE) | 2026-01-29 | — | — | US | disclosed |
| EP-4561968-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | Technische Universität München (DE) | 2025-06-04 | — | — | EP | disclosed |
| CN-119630622-A | Silicon-based fluoride acceptor groups for radiopharmaceuticals | 慕尼黑工业大学 | 2025-03-14 | — | — | CN | disclosed |
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2024-08-01 | — | — | US | disclosed |
| EP-4323017-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| WO-2002024741-A2 | ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM CHROMOSOME 7 | RYAN JAMES W (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2000022094-A2 | METHODS FOR INHIBITING OXIDATIVE MODIFICATION OF PROTEINS | KANSAS UNIVERSITY MEDICAL CENTER (US) | 2000-04-20 | — | — | WO | disclosed |
| EP-0415470-B1 | Aminopeptidase | DMV CAMPINA BV (NL) | 1995-01-04 | — | — | EP | disclosed |
| EP-0415470-A2 | Aminopeptidase | CAMPINA MELKUNIE B.V. (NL) | 1991-03-06 | — | — | EP | disclosed |
| JP-S62215599-A | GLYCITOL LYSINE DERIVATIVE | OTSUKA PHARMACEUT CO LTD | 1987-09-22 | — | — | JP | disclosed |
| EP-0127076-A2 | Histargin, a microbiological process for its preparation, its use as a medicament, and the strain Streptomyces roseoviridis having the ability to produce histargin | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1984-12-05 | — | — | EP | disclosed |
| US-3970597-A | COUPLERS FOR PROTEINS, ENZYMES; DYEABILITY | SOKOLOVSKY MORDECHAI | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | SSTR3, SLC43A1, SSTR1 | GPR139 1899/4885FOLH1 559/4885SLC6A5 206/4885 |
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | FOLR1, FOLR2, FOLH1 | GPR139 202/4885FOLH1 3/4885SLC6A5 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.